BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18619379)

  • 1. Perspectives of molecular imaging and radioimmunotherapy in lymphoma.
    Iagaru A; Goris ML; Gambhir SS
    Radiol Clin North Am; 2008 Mar; 46(2):243-52, viii. PubMed ID: 18619379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
    Specht L
    Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography.
    Bodet-Milin C; Kraeber-Bodéré F; Dupas B; Morschhauser F; Gastinne T; Le Gouill S; Campion L; Harousseau JL; Wegener WA; Goldenberg DM; Huglo D
    Haematologica; 2008 Mar; 93(3):390-7. PubMed ID: 18268287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma.
    Tirumani SH; LaCasce AS; Jacene HA
    PET Clin; 2015 Apr; 10(2):207-25. PubMed ID: 25829087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of FDG-PET imaging in the management of lymphoma.
    Kostakoglu L; Leonard JP; Coleman M; Goldsmith SJ
    Clin Adv Hematol Oncol; 2004 Feb; 2(2):115-21. PubMed ID: 16163171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of therapy for lymphoma.
    Jerusalem G; Hustinx R; Beguin Y; Fillet G
    Semin Nucl Med; 2005 Jul; 35(3):186-96. PubMed ID: 16098292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
    Shen YY; Kao A; Yen RF
    Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG PET CT assessment of treatment response after yttrium-90 ibritumomab tiuxetan radioimmunotherapy.
    Joyce JM; Degirmenci B; Jacobs S; McCook B; Avril N
    Clin Nucl Med; 2005 Aug; 30(8):564-8. PubMed ID: 16024958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of FDG PET in the management of childhood lymphomas--case proven or is the jury still out?
    Shankar A; Fiumara F; Pinkerton R
    Eur J Cancer; 2008 Mar; 44(5):663-73. PubMed ID: 18313916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of PET in lymphoma.
    Jhanwar YS; Straus DJ
    J Nucl Med; 2006 Aug; 47(8):1326-34. PubMed ID: 16883013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine-131-rituximab radio-immunotherapy.
    Bishton MJ; Hicks RJ; Westerman DA; Prince MH; Wolf M; Seymour JF
    Haematologica; 2008 May; 93(5):789-90. PubMed ID: 18450737
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
    Qiu L; Chen Y; Wu J
    Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies.
    England CG; Rui L; Cai W
    Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):517-532. PubMed ID: 27844106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging: staging and evaluation of lymphoma using nuclear medicine.
    Divgi C
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S11-8. PubMed ID: 15786021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients.
    Allen-Auerbach M; de Vos S; Czernin J
    Radiol Clin North Am; 2008 Mar; 46(2):199-211, vii. PubMed ID: 18619376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary duodenal lymphoma: successful rituximab treatment and evaluation by FDG-PET.
    Tanaka F; Tominaga K; Ochi M; Yamada T; Sasaki E; Shiba M; Watanabe T; Fujiwara Y; Uchida T; Oshitani N; Higuchi K; Arakawa T
    Hepatogastroenterology; 2007 Sep; 54(78):1658-61. PubMed ID: 18019688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of positron emission tomography with [18F] 2-fluoro-D-2-deoxyglucose (FDG-PET) in Hodgkin and non-Hodgkin's lymphoma.
    Chiusolo P; Sica S; Leone G
    Hematology; 2003 Dec; 8(6):403-8. PubMed ID: 14668036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early evaluation of tumor response to
    Kitajima K; Okada M; Kashiwagi T; Yoshihara K; Tokugawa T; Sawada A; Yoshihara S; Fujimori Y; Yamakado K
    Eur Radiol; 2019 Jul; 29(7):3935-3944. PubMed ID: 30899979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PET imaging for response assessment in lymphoma: potential and limitations.
    Schöder H; Moskowitz C
    Radiol Clin North Am; 2008 Mar; 46(2):225-41, viii. PubMed ID: 18619378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hodgkin's and non-Hodgkin's lymphomas.
    Rademaker J
    Radiol Clin North Am; 2007 Jan; 45(1):69-83. PubMed ID: 17157624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.